Dr Guei-Sheung (Rick) Liu is an internationally recognised expert in ophthalmic gene therapy. He has extensive experience devising innovative strategies to prevent and delay blindness associated with major ocular diseases.
Dr Liu earned his PhD from Kaohsiung Medical University in Taiwan and subsequently completed postdoctoral training at the O'Brien Institute and the Centre for Eye Research Australia (CERA). In 2017, Dr Liu established an independent research group at the University of Tasmania before returning to CERA in late 2021 to initiate a new genetic engineering research unit.
Dr Liu's current research focuses on applying genetic techniques to understand and develop the treatment for various ocular conditions, including common complex and rare "orphan" eye diseases. The insights garnered from his research have contributed to the development of clinically applicable gene therapies for managing eye diseases.
Additionally, his work investigates gene editing technologies, refining these cutting-edge genetic tools for the treatment of genetic eye disorders.

RNA editing is the next frontier in gene therapy – here’s what you need to know
Nov 22, 2024 11:25 am UTC| Insights & Views Science
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes...